Delving into the Latest Updates on Fibrin glue(Foundation For Biomedical Research And Innovation) with Synapse

Overview

Basic Info

Drug Type

Non-recombinant coagulation factor

Synonyms

Target

Fibrinogen

Action

stimulants

Mechanism

Fibrinogen stimulants

Therapeutic Areas

Otorhinolaryngologic DiseasesOther Diseases

Active Indication

Tympanic Membrane Perforation

Inactive Indication-

Originator Organization

Foundation For Biomedical Research And Innovation

Active Organization

Foundation For Biomedical Research And Innovation

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

BACKGROUND/AIMTracheal anastomosis is commonly indicated for patients with tracheal tumor, stenosis and tracheoesophageal fistula. This study was designed to evaluate the healing activity of topical application of platelet-rich plasma (PRP) jelly for tracheal reconstruction in a rabbit model.MATERIALS AND METHODSThirty-six healthy New Zealand White rabbits were assigned to three groups of 12 animals each. The control group underwent tracheal resection and anastomosis. The fibrin-glue group and PRP-jelly group underwent tracheal resection and anastomosis plus fibrin glue or PRP jelly application over the anastomosis and surgical field, respectively.RESULTSThe PRP jelly treatment enhanced the healing capacity by positive effects on healing rate, tissue fill, and volume fraction of fibroblasts during the 28 days following surgery.CONCLUSIONApplication of PRP jelly to tracheal anastomotic wounds can accelerate or improve the quality of repair.

02 Jan 2017·Artificial Cells, Nanomedicine, and BiotechnologyQ2 · ENGINEERING & TECHNOLOGY

Modified alginate and gelatin cross-linked hydrogels for soft tissue adhesive

Q2 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Mo, Xiumei ; Morsi, Yosry ; Fang, Jun ; Yuan, Liu ; Wu, Yu ; Gu, Qisheng ; Wei, Xiaojuan ; Al-Deyab, Salem S. ; El-Hamshary, Hany

Soft tissue adhesives made from natural hydrogel are attractive in clinical applications due to their excellent properties, such as high water content, good biocompatibility, low immune, good biodegradability. Hydrogels derived from natural polysaccharides and proteins are ideal components for soft tissue adhesive since they resemble the extracellular matrices of the tissue composed of various sugar and amino acids-based macromolecules. In this paper, a series of novel tissue adhesives mixed by aldehyde sodium alginate (ASA) with amino gelatin (AG) were developed and characterized. The effect of aldehyde content in ASA and amino group content in AG on the properties of ASA/AG cross-linked hydrogel was measured. The results showed the gelling time, swelling behavior and the bonding strength of the hydrogel can be tuned by varying the content of aldehyde groups in ASA and the content of amino groups in AG. The gelation time could be controlled within 4-18 min. When the aldehyde content of ASA is 75.24% and the amino content of AG is 0.61 mmol/g, the hydrogel almost has the adhesive strength equal to the commercially available adhesive ﬁbrin glue. So, this tunable ASA/AG hydrogels in this study could be a promising candidate as soft tissue adhesive and have a wide range of biomedical applications.

01 Aug 2015·Techniques in Coloproctology

Anal fistula closure with FiLaC: new hope or the same old story?

Author: Altomare, D F

Throughout the centuries human beings have suffered fromanal ﬁstula.The history of medicine is full of reports about thetreatment of this pathology and, in recent times, whenattention has focused on preserving continence and qualityof life has become a central issue in medical practice, manynew sphincter-saving techniques have been proposed.Few diseases have such a wide range of severity andanatomical variations. The disease spectrum ranges fromsimple submucosal ﬁstula tracts to an extrasphincteric ﬁs-tulas involving multiple tracts and, while the treatment ofthe simplest ones is easy and safe, the more complex ﬁs-tulas require expert surgeons and often multiple operations.The modern surgical approach to anal ﬁstulas includesseveral sphincter-saving procedures including the closureof the ﬁstula tract with plugs, ﬁbrin glue, or collagen pastewithout ﬁstulotomy (i.e., laying open) or by means of ﬁs-tulectomy (i.e., core-out technique) [1]. However, despiteseveral encouraging reports, though few randomized con-trolled trials, there is still some skepticism among colo-proctologists about the effectiveness of these newsphincter-saving procedures.A pretty new conservative proposal to treat anal ﬁstulainvolves the use of energy delivery devices (such as laser)to destroy the chronically inﬂamed connective tissue of theﬁstula tract by means of a probe inserted into the ﬁstulatract as is reported in this issue of the journal [2]. Actually,the idea of using laser energy is not completely new as itwas suggested in two studies in 1981 [3] and 1995 [4]butwith different techniques and energy devices.Giamundo et al. [2] draw attention to two critical aspectsof the management of this common and often frustratinganal disease. The ﬁrst concerns the treatment (or not) of theinternal opening of the ﬁstula. Surgeons of my generationhave been taught and, in turn, we have taught our students,that the key to success of anal ﬁstula treatment is the clo-sure of the primary oriﬁce, where the bacteria come from.Nowadays the proponents of the LIFT operation say thatjust the interruption the ﬁstula tract close to the internalopening is enough to get a 70 % or higher primary healingrate [5], even in complex anorectal ﬁstulas [6]. Similarly,FiLaC consists of blind cauterization of the tract withoutaddressing the internal opening with a long-term successrate of 71 % [2].The second issue concerns the management of the ﬁstulatract itself. Several attempts have been made to helpspontaneous healing using biological glues (ﬁbrin [7],collagen paste [8]), plugs of collagen matrix [9, 10] and aplethora of other methods including adipose-derived stemcells [11], but the results in the real world of surgicalpractice are often disappointing despite some enthusiastic(uncontrolled) reports (but we know from Feinstein that‘‘reports with enthusiasm have no controls and reports withcontrols have no enthusiasm’’ [12]). In the FiLaC techniquethe chronically inﬂamed connective tissue is ‘‘burned’’ bythe laser energy allowing tissue repair by the macrophagesand ﬁbroblasts coming from the surrounding healthy con-nective tissue [13]. The results obtained by the few authorswho have used this new technique are really exciting [2,13, 14] but, since the commonest bias in clinical research isto fall in love with our own ideas or personal technique, wedo need to test the reproducibility of this new technique onlarger series and to ‘‘pass the exam’’ of randomized con-trolled trials comparing the new procedure with othersurgical techniques used to treat anal ﬁstulas.

100 Deals associated with Fibrin glue(Foundation For Biomedical Research And Innovation)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tympanic Membrane Perforation	Phase 3	-	Foundation For Biomedical Research And Innovation	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P291 (EBMT2018)	Not Applicable	Hemorrhagic cystitis	63	Fibrin-glue	(aybigewclc) = jtwnzojphf vdizobuthn (vqjhtbpbqw ) View more	-	19 Nov 2018
AAO2013	Not Applicable	-	23	Fibrin glue-assisted intrascleral fixation of PC-IOL	(dwpnywaqii) = zjpyfxwnoz tqenzgphwc (xhcqejgxyy ) View more	Positive	17 Nov 2013
ARVO2002	Not Applicable	Blister	20	Cultured skin + Fibrin glue	(ztcorexskw) = txdwclbqaz vrguppyvgj (oudkpopijp )	Positive	01 Dec 2002
ARVO2002	Not Applicable	Blister	20	Free Electron Laser-treated Fibrin Glue (Cultured skin + Fibrin glue + FEL @ 7.7µm)	(ztcorexskw) = enngrkcrue vrguppyvgj (oudkpopijp )	Positive	01 Dec 2002

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data